Introduction Cardiovascular (CV) effects of once‐weekly subcutaneous (sc) semaglutide 0.5
and 1 mg and dulaglutide 1.5 mg are reported in their respective placebo‐controlled …

Background Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2
diabetes (T2D) available in subcutaneous (sc) and oral formulations. Two cardiovascular …

Background The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …

Aims To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation
of a glucagon‐like peptide‐1 receptor agonist. Materials and methods PIONEER 6 is a …

Background Establishing cardiovascular safety of new therapies for type 2 diabetes is
important. Safety data are available for the subcutaneous form of the glucagon-like peptide …

Aim To investigate the effects of semaglutide versus comparators on major adverse
cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] …

To exclude an excess risk of cardiovascular (CV) events, CV outcomes trials (CVOTs) have
assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 …

Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are recommended for glycaemic
management in patients with type 2 diabetes (T2D). Oral semaglutide, the first oral GLP …

OBJECTIVE Semaglutide, a glucagon-like peptide 1 receptor agonist, reduced major
adverse cardiovascular events (MACE) in people with type 2 diabetes (T2D) at high risk of …

In individuals with type 2 diabetes, glycaemic control and cardiovascular risk factor
management reduces the likelihood of late-stage diabetic complications. Guidelines …